Ghadersohi Saied, Tan Bruce K
Department of Otolaryngology-Head and Neck Surgery, Northwestern University, Feinberg School of Medicine, 676 North Saint Clair Suite #1325, Chicago, IL 60611, USA.
Department of Otolaryngology-Head and Neck Surgery, Northwestern University, Feinberg School of Medicine, 676 North Saint Clair Suite #1325, Chicago, IL 60611, USA.
Otolaryngol Clin North Am. 2017 Dec;50(6):1135-1151. doi: 10.1016/j.otc.2017.08.009. Epub 2017 Sep 28.
Chronic rhinosinusitis (CRS) and allergic rhinitis (AR) are chronic conditions causing nasal inflammation. CRS is increasingly recognized as a chronic inflammatory process rather than a chronic infection. Although the primary initiating factors in CRS remain unclear, AR is driven by IgE-mediated hypersensitivity to environmental allergens. Understanding the underlying inflammatory pathways and disease endotypes are driving innovation toward novel pharmacotherapies targeting critical mediators implicated in CRS and AR, including IL-4, IL-13, IL-5, IgE, and epithelial initiators IL-33 and TSLP. Extensive investigations are needed to determine the role, timing, predictive prognostic factors and long-term safety and efficacy of these agents.
慢性鼻-鼻窦炎（CRS）和变应性鼻炎（AR）是引起鼻腔炎症的慢性疾病。CRS越来越被认为是一种慢性炎症过程而非慢性感染。尽管CRS的主要起始因素仍不明确，但AR是由IgE介导的对环境过敏原的超敏反应所驱动。了解潜在的炎症途径和疾病内型正在推动针对CRS和AR中涉及的关键介质（包括IL-4、IL-13、IL-5、IgE以及上皮起始因子IL-33和TSLP）的新型药物疗法的创新。需要进行广泛的研究以确定这些药物的作用、时机、预测性预后因素以及长期安全性和疗效。
